RyMat Inc
Stuart Silverman
CEO & Founder

RyMat Inc.

Solution Provider to the Pharmaceutical Industry

Apothecations

Pharmaceutical Industry Topics and Tips

view:  full / summary

Brief Look At Different Types Of Pharmaceutical Companies

Posted on August 7, 2016 at 7:50 AM Comments comments (2)

Our Aging Population and Increasing Dependence on Prescription Medicines

Posted on March 12, 2016 at 4:10 PM Comments comments (3)


Better Living Through Chemistry

 

Our Aging Population and Increasing Dependence on Prescription Medicines

 

As of December 2, 2015, the United States has a total resident population of 322,267,564, making it the third most populous country in the world.

Read Full Post »

Breakthrough Therapy Designation

Posted on March 11, 2016 at 3:55 PM Comments comments (0)


RyMat Inc. FDA Drug Approval & Applications Series

Volume V

Breakthrough Therapy Designation

Breakthrough therapy is a United States Food and Drug Administra...

Read Full Post »

FDA Orphan Drug Designation (with editorial)

Posted on March 6, 2016 at 4:10 PM Comments comments (0)


RyMat Inc. FDA Drug Approval & Applications Series

Volume IV

FDA Orphan Drug Designation

An orphan drug is a pharmaceutical agent that has been developed specifically...

Read Full Post »

FDA Priority Review (plus editorial comments)

Posted on March 5, 2016 at 3:10 PM Comments comments (0)


RyMat Inc. FDA Drug Approval & Applications Series

Volume III

FDA Priority Review (plus editorial comments)

The priority review is an incentive for companies to invest in new drugs and vacc...

Read Full Post »

FDA Fast Track Approval Program

Posted on February 28, 2016 at 1:15 PM Comments comments (0)



RyMat Inc. FDA Drug Approval & Applications Series

Volume II

FDA Fast Track Approval Program

Section 506(b) of the FD&C Act provides for the designation of a drug as a fast track product &...

Read Full Post »

FDA Accelerated Approval Program

Posted on February 27, 2016 at 2:55 PM Comments comments (0)


FDA Drug Approval & Applications Series

Volume I

FDA Accelerated Approval Program

The accelerated approval provisions of FDASIA in section 506(c) of the FD&C Act provide that FDA may grant accelerated approval to:

Read Full Post »

Rss_feed